3D Medicines Moves Envafolimab Toward Full Approval in China

3D Medicines, Inc. ( (HK:1244) ) has shared an update.

3D Medicines Inc. has announced that China’s National Medical Products Administration has formally accepted its supplemental application to convert Envafolimab’s status from conditional approval to full regular approval as a domestically produced drug, covering a 200mg (1.0ml) per vial specification. The filing, submitted by subsidiary 3D Medicines (Sichuan) Co., Ltd. and accepted on February 2, 2026, marks a key regulatory step that could solidify Envafolimab’s market position in China and strengthen 3D Medicines’ role in the PD-L1 inhibitor segment, following earlier licensing deals that expand the drug’s reach in mainland China and multiple international territories.

The requested approval transition, if granted, would reduce regulatory uncertainty around Envafolimab’s current indication in previously treated MSI-H/dMMR advanced solid tumors and may support broader commercial uptake. However, the company cautions that successful development or marketing of Envafolimab for any future indications beyond its existing approval is not assured, signaling ongoing clinical and regulatory risk for investors and partners as 3D Medicines advances its oncology portfolio.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

More about 3D Medicines, Inc.

3D Medicines Inc. is a biopharmaceutical company focused on oncology, developing and commercializing innovative cancer therapies. Its core portfolio includes Envafolimab (KN035), a recombinant single-domain PD-L1 antibody fusion and the world’s first subcutaneous PD-L1 inhibitor approved in China for MSI-H/dMMR advanced solid tumors, with regional commercialization partnerships across China and emerging markets.

Average Trading Volume: 271,724

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.15B

For a thorough assessment of 1244 stock, go to TipRanks’ Stock Analysis page.